Search in:

Acta Oncologica Volume 57, 2018 - Issue 5

Journal homepage

Open access

2,459

Views

CrossRef citations to date

Altmetric

Original Articles: Urologic Tumours

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Frede DonskovDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark; Correspondence[email protected]
View further author information

Niels Viggo JensenDepartment of Oncology, Odense University Hospital, Odense, Denmark; View further author information

Torben Smidt-HansenDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark; View further author information

Line BrøndumDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark; View further author information

Poul GeertsenDepartment of Oncology, Herlev Hospital, University of Copenhagen, DenmarkView further author information

Pages 589-594 | Received 17 Nov 2017, Accepted 22 Jan 2018, Published online: 02 Feb 2018

Cite this article
https://doi.org/10.1080/0284186X.2018.1433324
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (16)

Aska Drljevic-Nielsen, Nikolaj Skou, Jill R Mains, Erik M Pedersen, Finn Rasmussen & Frede Donskov. (2023) Late adverse events to iodinated contrast media in patients treated with IL-2: a safety report from the Danish Renal Carcinoma Group (DaRenCa) study – 1. Acta Radiologica.
Crossref

Ligang Wang, Hao Wu, Ying Wang, Songcheng Xu, Chen Yang, Tingting Zhang, Yang Liu, Fuwei Wang, Weinan Chen, Jianchun Li & Litao Sun. (2023) Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways. Heliyon 9:8, pages e19154.
Crossref

Angela Aldin, Burcu Besiroglu, Anne Adams, Ina Monsef, Vanessa Piechotta, Eve Tomlinson, Carolin Hornbach, Nadine Dressen, Marius Goldkuhle, Philipp Maisch, Philipp Dahm, Axel Heidenreich & Nicole Skoetz. (2023) First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2023:5.
Crossref

Kasper Munch Lauridsen, Marianne Hokland, Sinan Al-Karradi, Holger Jon Møller, Frede Donskov & Morten Nørgaard Andersen. (2022) Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 72:2, pages 461-473.
Crossref

Farbod Ghobadinezhad, Zhila Izadi, Marzieh Ebrahimi & Nima Rezaei. 2023.

Ming-Yee Sun & Sonu M. M. Bhaskar. (2022) Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis. Diagnostics 12:12, pages 2954.
Crossref

Mohammed Merae Alshahrani. (2022) A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers. Saudi Journal of Biological Sciences 29:4, pages 2072-2084.
Crossref

Ercília Rita Mondlane, Pedro Abreu-Mendes, Diana Martins, Rui Cruz & Fernando Mendes. (2021) The role of immunotherapy in advanced renal cell carcinoma. International braz j urol 47:6, pages 1228-1242.
Crossref

Aska Drljevic-Nielsen, Finn Rasmussen, Patricia Switten Nielsen, Christina Stilling, Kennet Thorup, Jill Rachel Mains, Hans Henrik Torp Madsen & Frede Donskov. (2021) Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. European Radiology Experimental 5:1.
Crossref

Aska Drljevic-Nielsen, Finn Rasmussen, Jill Rachel Mains, Kennet Thorup & Frede Donskov. (2021) Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma. Scientific Reports 11:1.
Crossref

Jamal Majidpoor & Keywan Mortezaee. (2021) Interleukin-2 therapy of cancer-clinical perspectives. International Immunopharmacology 98, pages 107836.
Crossref

Shouki Bazarbashi, Abdullah Alsharm, Faisal Azam, Hazem El Ashry & Jamal Zekri. (2020) The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. Future Oncology 16:34, pages 2879-2896.
Crossref

Aska Drljevic-Nielsen, Finn Rasmussen, Jill R. Mains, Kennet Thorup & Frede Donskov. (2020) Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. Translational Oncology 13:10, pages 100829.
Crossref

Tobias Bald, Matthew F. Krummel, Mark J. Smyth & Kevin C. Barry. (2020) The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nature Immunology 21:8, pages 835-847.
Crossref

Weilan Wang, Le Cai, Bingkun Xiao & Rongqing Huang. (2020) Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal 22:7.
Crossref

Niels Fristrup & Frede Donskov. (2019) Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical Genitourinary Cancer 17:4, pages 254-259.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Articles from other publishers (16)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Citations (16)

Articles from other publishers (16)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date